

June 20, 2014

VIA HAND DELIVERY

AUSA Kenneth Harmon
United States Attorney's Office
District of Colorado
1225 Seventeenth Street, Suite 700
Denver, CO 80202

Re: Scott Dittman / Fusion Pharm, Inc.

Dear Ken:

During our recent meeting together, you suggested that I take a hard look at the sales revenues for Fusion Pharm, Inc. As promised earlier this week, with this letter I am transmitting to you a compilation of documents yielded by our preliminary efforts to review transactions for sales of pods manufactured by Fusion Pharm since 2011.

By my count, the attached records and materials document a total of sixty seven (67) pods sold. Fifty nine (59) pods appear to have been delivered to buyers, and eight (8) have yet to be delivered.


Attached hereto you will find a series of tabs, each of which corresponds to a customer of the company during that period, and under which you will find records or other evidence documenting such sales transactions. The records attached are not complete - - the government has seized most of the company's records, so it has been difficult to assemble complete records sets for each sale. What you will find, however, depending on availability of records for various transactions, are copies of proposals, contracts, excerpts of bank records, copies of checks, shipping, customs, and inspection documents, and photographs of pods. In most cases, signed copies of documents were not available because the government seized the signed copies, so we have had to make do with copies attached to email messages. Most of these records came from Scott Dittman's email records, banking records available online, or from Fusion Pharm customers who were interviewed by my investigator, and who sent us photos of pods or records upon my investigator's request.

Kenneth Harmon
June 20, 2014
Page 2

I apologize that it has taken us a couple of weeks to put together this (admittedly incomplete) set of documents evidencing these sales transactions, but you have the company's records, and I needed to hire an investigator to conduct interviews of customers. Even though the records are not complete, I am fairly well satisfied that the company sold north of five dozen pods, and got paid for them, either directly by the purchaser, or by Mead Point, the company publicly disclosed as the contract sales agency for Fusion Pharm.

I confess that in light of what we have been able to document readily even without the benefit of the company's full business records (with more substantiation available from public sources), I am puzzled as to why the government would believe that these sales had not taken place. I would like to discuss the matter further with you when you have time.

Very truly yours,



William L. Taylor

Enclosures

cc: Ian Karpel, Assistant Director
United States Securities and Exchange Commission